Daiichi Sankyo

Diversified pharma

4568 · TSE · Japan

Public Market Listing

4568TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Daiichi Sankyo are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(21 total)
21Total Assets
10Approved
6Phase 3 / Filed
5Phase 1–2 / Early
25Diseases
Quick filter:
Showing 21 of 21 assets
Target & Modality
Bempedoic acid(Nexletol)
Approved
ATP citrate lyaseSmall molecule
Atherosclerotic Cardiovascular Disease
Approved
ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule
Atherosclerotic Cardiovascular Disease
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer
Canagliflozin(Invokana)
Approved
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease
Approved
TROP2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerBladder / Urothelial Cancer
HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma
Approved
RANKLMonoclonal antibody
Rheumatoid ArthritisOsteoporosis
Ferric carboxymaltose(Injectafer / Ferinject)
Approved
Iron repletionOther
Heart FailureChronic Kidney DiseaseIron Deficiency Anemia
Approved
CGRP ligandMonoclonal antibody
Migraine
Approved
FLT3Small molecule
Acute Myeloid Leukemia
Approved
HER2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Phase 3
RANKLMonoclonal antibody
Non-Small Cell Lung CancerMultiple MyelomaBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Esaxerenone(Minnebro)No recent activity
Phase 3
Mineralocorticoid receptorSmall molecule
Hypertension
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung CancerMetastatic Castration-Resistant Prostate CancerSmall Cell Lung CancerEsophageal Cancer
Esophageal Squamous Cell Carcinoma
Phase 3
α2δ-1 subunit of voltage-gated calcium channelsSmall molecule
Diabetic Peripheral Neuropathic Pain
Phase 3
HER3Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(76 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (16)
January 2027 (1)
Datopotamab DeruxtecanPhase 3Metastatic Non-small Cell Lung Cancer
Est. primary completion 2027-01-11 · NCT06417814 · CT.gov ↗
What to watch
February 2027 (1)
Trastuzumab DeruxtecanPhase 2Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Est. primary completion 2027-02-10 · NCT06271837 · CT.gov ↗
What to watch
March 2027 (1)
Trastuzumab DeruxtecanPhase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric …
Est. primary completion 2027-03-23 · NCT04482309 · CT.gov ↗
What to watch
April 2027 (1)
Ifinatamab DeruxtecanPhase 1/2Advanced Solid Tumor, Malignant Solid Tumor
Est. primary completion 2027-04-30 · NCT04145622 · CT.gov ↗
What to watch
May 2027 (4)
QuizartinibPhase 1/2Acute Myeloid Leukemia
Est. primary completion 2027-05-01 · NCT03793478 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Breast Cancer; HER2-positive; Metastatic
Est. primary completion 2027-05-03 · NCT04784715 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 2Gastric Cancer
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + Trastuzumab DeruxtecanPhase 1/2Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5 …
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
June 2027 (1)
Ifinatamab DeruxtecanPhase 1/2Oesophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-12 · NCT07405151 · CT.gov ↗
What to watch
July 2027 (2)
Ifinatamab DeruxtecanPhase 1/2Extensive Stage-small Cell Lung Cancer
Est. primary completion 2027-07-20 · NCT06362252 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-07-28 · NCT06103864 · CT.gov ↗
What to watch
September 2027 (1)
Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-09-01 · NCT05629585 · CT.gov ↗
What to watch
October 2027 (2)
Datopotamab DeruxtecanPhase 2Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer …
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-10-01 · NCT05950945 · CT.gov ↗
What to watch
November 2027 (2)
Est. primary completion 2027-11-01 · NCT05687266 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 2Gastroesophageal Adenocarcinoma
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
2028 (21)
January 2028 (2)
Ifinatamab DeruxtecanPhase 1/2Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 3Small Cell Lung Cancer
Est. primary completion 2028-01-30 · NCT06203210 · CT.gov ↗
What to watch
February 2028 (4)
Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2028-02-02 · NCT07205822 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + Trastuzumab DeruxtecanPhase 1/2Advanced Solid Malignancies
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Advanced Cancer, Metastatic Cancer
Est. primary completion 2028-02-17 · NCT06174987 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 2/3Solid Cancer
Est. primary completion 2028-02-29 · NCT06161025 · CT.gov ↗
What to watch
March 2028 (2)
Datopotamab DeruxtecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-03-21 · NCT06350097 · CT.gov ↗
What to watch
valemetostat tosylate · EzharmiaPhase 1/2Non-small Cell Lung Cancer, Lung Cancer
Est. primary completion 2028-03-30 · NCT06644768 · CT.gov ↗
What to watch
May 2028 (1)
Patritumab DeruxtecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
June 2028 (5)
Trastuzumab DeruxtecanPhase 3Gastric Cancer, Gastroesophageal Junction Cancer
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 3Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-06-01 · NCT06644781 · CT.gov ↗
What to watch
QuizartinibPhase 2Acute Myeloid Leukemia, Leukemia
Est. primary completion 2028-06-06 · NCT06824168 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Biliary Tract Cancer
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 3Prostate Cancer, Prostatic Neoplasms
Est. primary completion 2028-06-26 · NCT06925737 · CT.gov ↗
What to watch
July 2028 (1)
Ifinatamab DeruxtecanPhase 1/2Recurrent or Metastatic Solid Tumors
Est. primary completion 2028-07-25 · NCT06330064 · CT.gov ↗
What to watch
August 2028 (1)
DS-3939aPhase 1/2Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2028-08-11 · NCT05875168 · CT.gov ↗
What to watch
November 2028 (2)
Trastuzumab DeruxtecanPhase 3Ovarian Cancer
Est. primary completion 2028-11-01 · NCT06819007 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
December 2028 (3)
Datopotamab DeruxtecanPhase 1/2Advanced Solid Tumors That Are MTAP Deficient
Est. primary completion 2028-12-04 · NCT06130553 · CT.gov ↗
What to watch
Patritumab DeruxtecanPhase 1/2Gastrointestinal Cancer
Est. primary completion 2028-12-07 · NCT06596694 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 2Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-12-16 · NCT07941609 · CT.gov ↗
What to watch
2029 (16)
January 2029 (2)
Trastuzumab DeruxtecanPhase 3Endometrial Cancer
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2029-01-29 · NCT07291037 · CT.gov ↗
What to watch
February 2029 (1)
Ifinatamab DeruxtecanPhase 1/2Small Cell Lung Cancer
Est. primary completion 2029-02-15 · NCT06780137 · CT.gov ↗
What to watch
March 2029 (1)
Raludotatug DeruxtecanPhase 1/2Ovarian Cancer Recurrent
Est. primary completion 2029-03-27 · NCT06843447 · CT.gov ↗
What to watch
April 2029 (2)
Datopotamab DeruxtecanPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
May 2029 (1)
Datopotamab DeruxtecanPhase 3Metastatic Non Small Cell Lung Cancer
Est. primary completion 2029-05-11 · NCT05555732 · CT.gov ↗
What to watch
June 2029 (1)
Datopotamab DeruxtecanPhase 2/3Urothelial Cancer, Bladder Cancer
Est. primary completion 2029-06-01 · NCT07129993 · CT.gov ↗
What to watch
July 2029 (1)
Raludotatug DeruxtecanPhase 3Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
Est. primary completion 2029-07-01 · NCT07791732 · CT.gov ↗
What to watch
August 2029 (1)
Patritumab DeruxtecanPhase 1/2Lung Neoplasm Malignant
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
September 2029 (2)
Patritumab DeruxtecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 1/2Urothelial Cancer, Non-small Cell Lung Cancer
Est. primary completion 2029-09-30 · NCT07890714 · CT.gov ↗
What to watch
December 2029 (4)
Raludotatug DeruxtecanPhase 1/2Small Cell Lung Carcinoma
Est. primary completion 2029-12-10 · NCT04938817 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 2Advanced Solid Tumor, Metastatic Solid Tumors
Est. primary completion 2029-12-30 · NCT06660654 · CT.gov ↗
What to watch
Patritumab DeruxtecanPhase 2Breast Neoplasms, Breast Cancer
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (11)
February 2030 (1)
Trastuzumab DeruxtecanPhase 3Endometrial Cancer
Est. primary completion 2030-02-26 · NCT07022483 · CT.gov ↗
What to watch
March 2030 (1)
Datopotamab DeruxtecanPhase 3Metastatic Non Small Cell Lung Cancer
Est. primary completion 2030-03-04 · NCT05215340 · CT.gov ↗
What to watch
April 2030 (1)
Trastuzumab DeruxtecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
May 2030 (1)
Datopotamab DeruxtecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
June 2030 (1)
QuizartinibPhase 3Leukemia
Est. primary completion 2030-06-26 · NCT06578247 · CT.gov ↗
What to watch
July 2030 (2)
Trastuzumab DeruxtecanPhase 3Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
DS-3939a + DS-1103aPhase 1/2Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Est. primary completion 2030-07-31 · NCT07739966 · CT.gov ↗
What to watch
September 2030 (1)
Datopotamab DeruxtecanPhase 3High-risk Muscle Invasive Urothelial Carcinoma
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
November 2030 (2)
Patritumab DeruxtecanPhase 2Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer …
Est. primary completion 2030-11-19 · NCT06172478 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 1/2Small Cell Lung Cancer Extensive Stage
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
December 2030 (1)
Patritumab DeruxtecanPhase 1/2Malignant Neoplasm
Est. primary completion 2030-12-30 · NCT06941272 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Patritumab DeruxtecanPhase 1/2Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Est. primary completion 2031-01-01 · NCT07701941 · CT.gov ↗
What to watch
August 2031 (2)
Ifinatamab DeruxtecanPhase 1/2Malignant Neoplasm
Est. primary completion 2031-08-17 · NCT07630974 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 3Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2031-08-31 · NCT07743164 · CT.gov ↗
What to watch
October 2031 (1)
Ifinatamab DeruxtecanPhase 1/2Castration-Resistant Prostatic Cancer, Metastasis
Est. primary completion 2031-10-01 · NCT06863272 · CT.gov ↗
What to watch
2032 (7)
January 2032 (1)
Ifinatamab DeruxtecanPhase 1/2Esophageal Squamous Cell Carcinoma
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Patritumab Deruxtecan + Ifinatamab DeruxtecanPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch
March 2032 (4)
Est. primary completion 2032-03-02 · NCT06780098 · CT.gov ↗
What to watch
Ifinatamab Deruxtecan + Raludotatug DeruxtecanPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2032-03-12 · NCT06780085 · CT.gov ↗
What to watch
Patritumab DeruxtecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2032-03-12 · NCT06731907 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 3Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2032-03-19 · NCT07776691 · CT.gov ↗
What to watch
August 2032 (1)
Patritumab DeruxtecanPhase 1/2Breast Neoplasms, Breast Cancer
Est. primary completion 2032-08-02 · NCT06686394 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
Patritumab DeruxtecanPhase 3Breast Neoplasms
Est. primary completion 2033-07-14 · NCT07060807 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(12)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026ApprovalTrastuzumab DeruxtecanEU approves Enhertu as adjuvant monotherapy in HER2-positive early breast cancer
EU, EC · Source ↗
25 September 2026WithdrawalIfinatamab DeruxtecanUS BLA for ifinatamab deruxtecan in pretreated ES-SCLC voluntarily withdrawn
US, FDA · Daiichi Sankyo · Source ↗
14 September 2026Topline resultTrastuzumab DeruxtecanDESTINY-Lung04: Enhertu met its PFS primary endpoint vs pembrolizumab plus chemotherapy
AstraZeneca; Daiichi Sankyo · Source ↗
1 September 2026ApprovalTrastuzumab DeruxtecanEnhertu with pertuzumab approved in the EU for first-line HER2-positive metastatic breast cancer
EU, EC/EMA · Source ↗
5 August 2026WithdrawalLasmiditan (Reyvow)FDA withdraws approval of NDA 211280 (Federal Register 2026-13616)
US, FDA · Source ↗
31 July 2026ApprovalDatopotamab DeruxtecanDatroway approved in the EU for first-line metastatic TNBC in patients who are not candidates for immunotherapy
EU, EC/EMA · Source ↗
7 September 2025Topline resultIfinatamab DeruxtecanIDeate-Lung01 (NCT05280470) Phase 2: confirmed objective response rate 48.2% in 137 previously treated ES-SCLC patients
29 May 2025WithdrawalPatritumab DeruxtecanUS BLA for patritumab deruxtecan in EGFR-mutated NSCLC voluntarily withdrawn
US, FDA · Daiichi Sankyo and Merck & Co. · Source ↗
24 December 2024WithdrawalDatopotamab DeruxtecanDato-DXd EU MAA withdrawn for nonsquamous NSCLC
EU, EMA · Source ↗
26 June 2024Complete response letterPatritumab DeruxtecanFDA complete response letter for the patritumab deruxtecan BLA (third-party manufacturing inspection)
US, FDA · Daiichi Sankyo and Merck & Co. · Source ↗
22 September 2023Topline resultDatopotamab DeruxtecanTROPION-Breast01 topline: PFS met
Daiichi Sankyo · Source ↗
3 July 2023Topline resultDatopotamab DeruxtecanTROPION-Lung01 topline: PFS met, OS not significant at interim
Daiichi Sankyo · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$14.0B$3.0B$3.1B—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$12.4B$2.8B$4.3B—report ↗
2023-FY$9.4B$2.5B$3.3B—report ↗
2022-FY$9.3B$2.3B$5.4B—report ↗